NCT01573663已完成1 期
Open Label, Randomized, 3-sequence Crossover Study to Evaluate the Drug-drug Interaction Between Ambroxol HCl and Levodropropizine in Healthy Male Volunteers
Hanmi Pharmaceutical Company Limited1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 21
- 试验地点
- 1
- 主要终点
- AUClast
研究概览
简要总结
The purpose of this study is to evaluate the drug-durg interaction between ambroxol and levodropropizine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male
- •Age between 20 and 55
- •Signed informed consent
排除标准
- •Has a history of hypersensitivity to IP ingredients
- •Hypotension or hypertension
- •Has a history of acute infection within 14 days of screening
研究组 & 干预措施
Ambroxol and Levodropropizine
Experimental
干预措施: Ambroxol and Levodropropizine (Drug)
Ambroxol
Active Comparator
干预措施: Ambroxol (Drug)
Levodropropizine
Active Comparator
干预措施: Levodropropizine (Drug)
结局指标
主要结局
AUClast
时间窗: 0-48hrs
Cmax
时间窗: 0-48hrs
次要结局
- Tmax(0-48hrs)
- T1/2(0-48hrs)
- AUCinf(0-48hrs)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male VolunteersHealthyNCT02194283Boehringer Ingelheim34
已完成
2 期
Ambroxol in Disease Modification in Parkinson DiseaseParkinson DiseaseNCT02941822University College, London23
已完成
2 期
Ambroxol as a Disease-modifying Treatment in GBA-PDGBA Gene MutationParkinson DiseaseNCT05287503Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta65
尚未招募
1 期
Ambroxol as a Novel Disease Modifying Treatment for Lewy Body DementiaLewy Body DiseaseNCT04405596Lawson Health Research Institute15
已完成
3 期
Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore ThroatPharyngitisNCT00525044Boehringer Ingelheim249